CanBas Co

CanBas Co Altman Z-Score

The Altman Z-Score of CanBas Co (4575.T) as of Oct 18, 2026 is 54.95. In the previous year, Altman Z-Score was 79.92 — a change of -31.25% (lower).

Altman Z-Score

54.95

YoY

-31.25%

Last updated:

Altman Z-Score of CanBas Co is 2026 54.95 . Altman Z-Score of CanBas Co was 2025 79.92 . It decreases by -31.25% lower compared to the previous year.

The CanBas Co Altman Z-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Altman Z-Score
Date
Altman Z-Score
Jan 1, 2019
27.38 JPY
Jan 1, 2020
-2.25 JPY
Jan 1, 2021
-0.70 JPY
Jan 1, 2022
-4.53 JPY
Jan 1, 2023
51.55 JPY
Jan 1, 2024
92.73 JPY
Jan 1, 2025
79.92 JPY
Jan 1, 2026
54.95 JPY
The CanBas Co Altman Z-Score history
YEARAltman Z-ScoreYoY
54.95-31.25%
79.92-13.82%
92.73+79.89%
51.55-1,237.71%
-4.53+547.95%
-0.70-68.97%
-2.25-108.23%
27.38-27.36%
37.70-70.95%
129.79-44.59%
234.21-14.20%
272.99+122.37%
122.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Altman Z-Score of CanBas Co is 54.95 in 2026.

On Eulerpool you can find the complete historical development of Altman Z-Score CanBas Co since 2006 – with annual values, charts, and detailed analysis.

The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — CanBas Co

All Key Metrics — CanBas Co